Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser

Selected Publications

  • Szabadkai I, Torka R, Garamvölgyi R, Baska F, Gyulavári P, Boros S, Illyés E, Choidas A, Ullrich A and Örfi L (2018):
     
    Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
    J Med Chem. doi:10.1021/acs.jmedchem.8b00672
  • Onken J, Vajkoczy P, Torka R, Hempt C, Patsouris V, Heppner FL and Radke J (2017):
     
    Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival.
    Oncotarget. 8(31):50403-50414
  • Baumann C, Ullrich A and Torka R (2017):
     
    GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance.
    Mol Oncol. 11(10):1430-1447
  • Onken J, Torka R, Korsing S, Radke J, Krementeskaia I, Nieminen M, Bai X, Ullrich A, Heppner F and Vajkoczy P (2016):
     
    Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Oncotarget. 7(9):9876-89
  • Pénzes K, Baumann C, Szabadkai I, Örfi L, Kéri G, Ullrich A and Torka R (2014):
     
    Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Cancer Biol Ther. 15(11):1571-82
  • Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T and Kéri G (2014):
     
    Discovery andBiological Evaluation of Novel Dual EGFR/c-Met Inhibitors.
    ACS Med Chem Lett. 5(4):298-303
  • Torka R, Pénzes K, Gusenbauer S, Baumann C, Szabadkai I, Örfi L, Kéri G and Ullrich A (2014):
     Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Neoplasia. 16(4):301-18
  • Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP, Cronin SJ, Nitsch R, Schultz-Fademrecht C, Eickhoff J, Menninger S, Unger A, Torka R, Gruber T, Hinterleitner R, Baier G, Wolf D, Ullrich A, Klebl BM and Penninger JM (2014):
     
    The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
    Nature. 507(7493):508-12
  • Lorenz K, Grashoff C, Torka R, Sakai T, Langbein L, Bloch W, Aumailley M and Fässler R (2007):
     Integrin-linked kinase is required for epidermal and hair follicle morphogenesis.
    J Cell Biol. 177(3):501-13
  • Torka R, Thuma F, Herzog V and Kirfel G (2006):
     
    ROCK signaling mediates the adoption of different modes of migration and invasion in human mammary epithelial tumor cells.
    Exp Cell Res. 312(19):3857-71
  • Bollmann R, Méhes G, Torka R, Speich N, Schmitt C and Bollmann M (2003):
     Determination of features indicating progression in atypical squamous cells with undetermined significance: human papillomavirus typing and DNA ploidy analysis from
    liquid-based cytologic samples.
    Cancer. 99(2):113-7
  • Bollmann R, Méhes G, Torka R, Speich N, Schmitt C and Bollmann M (2003):
     Human papillomavirus typing and DNA ploidy determination of squamous intraepithelial lesions in liquid-based cytologic samples.
    Cancer. 99(1):57-62
  • Bollmann R, Torka R, Schmitz J, Bollmann M and Méhes G (2002):
     
    Determination of ploidy and steroid receptor status in breast cancer by laser scanning cytometry.
    Cytometry. 50(4):210-5

 

 

Direktor:
Prof. Dr. Guido Posern

AG Signaltransduktion: 
Leiter:    Robert Torka 
Telefon: (0345) 557-3820 
Email:     Email

Hausanschrift:
Institut für Physiologische Chemie
Hollystrasse 1
06114 Halle (Saale)

Assistenz der Institutsleitung:
Ines Knipping
Telefon: (0345) 557-3812 
Fax:        (0345) 557-3811
Email:    Email